Articles
Biosimilars: A Portrait
March 4, 2009
•Article: Biosimilars: A Portrait
By Beate Hötzl and Hermann Peters
Known under various labels — generic biologicals or follow-on biologics, for instance — biosimilars represent an extraordinary opportunity for generics companies. Roughly $10B worth of brand-name biopharmaceuticals, many of which cost $1000/month or more per patient, will lose their patent protection within the next three years. Because of the blockbuster earnings of many biopharmaceuticals during their patent lifetimes, generics companies will inevitably try to produce and market lower-priced biosimilar versions. But important differences between these and traditional chemical-based generics will complicate the entry of biosimilars to the market.
Reprinted with permission from BioProcess International 4(4):16-18 (April 2006)
Click Here To Download:•Article: Biosimilars: A Portrait
